• Je něco špatně v tomto záznamu ?

Hybridization Approach Toward Novel Antituberculars: Design, Synthesis, and Biological Evaluation of Compounds Combining Pyrazinamide and 4-Aminosalicylic Acid

G. Bouz, P. Šlechta, O. Jand'ourek, K. Konečná, P. Paterová, P. Bárta, M. Novák, R. Kučera, NK. Dal, F. Fenaroli, J. Zemanová, M. Forbak, J. Korduláková, O. Pavliš, P. Kubíčková, M. Doležal, J. Zitko

. 2023 ; 9 (1) : 79-96. [pub] 20221228

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004608

Apart from the SARS-CoV-2 virus, tuberculosis remains the leading cause of death from a single infectious agent according to the World Health Organization. As part of our long-term research, we prepared a series of hybrid compounds combining pyrazinamide, a first-line antitubercular agent, and 4-aminosalicylic acid (PAS), a second-line agent. Compound 11 was found to be the most potent, with a broad spectrum of antimycobacterial activity and selectivity toward mycobacterial strains over other pathogens. It also retained its in vitro activity against multiple-drug-resistant mycobacterial strains. Several structural modifications were attempted to improve the in vitro antimycobacterial activity. The δ-lactone form of compound 11 (11') had more potent in vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv. Compound 11 was advanced for in vivo studies, where it was proved to be nontoxic in Galleria mellonella and zebrafish models, and it reduced the number of colony-forming units in spleens in the murine model of tuberculosis. Biochemical studies showed that compound 11 targets mycobacterial dihydrofolate reductases (DHFR). An in silico docking study combined with molecular dynamics identified a viable binding mode of compound 11 in mycobacterial DHFR. The lactone 11' opens in human plasma to its parent compound 11 (t1/2 = 21.4 min). Compound 11 was metabolized by human liver fraction by slow hydrolysis of the amidic bond (t1/2 = 187 min) to yield PAS and its starting 6-chloropyrazinoic acid. The long t1/2 of compound 11 overcomes the main drawback of PAS (short t1/2 necessitating frequent administration of high doses of PAS).

000      
00000naa a2200000 a 4500
001      
bmc23004608
003      
CZ-PrNML
005      
20240522135315.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acsinfecdis.2c00433 $2 doi
035    __
$a (PubMed)36577009
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bouz, Ghada $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, Hradec Králové 500 05, Czech Republic $1 https://orcid.org/0000000320245788
245    10
$a Hybridization Approach Toward Novel Antituberculars: Design, Synthesis, and Biological Evaluation of Compounds Combining Pyrazinamide and 4-Aminosalicylic Acid / $c G. Bouz, P. Šlechta, O. Jand'ourek, K. Konečná, P. Paterová, P. Bárta, M. Novák, R. Kučera, NK. Dal, F. Fenaroli, J. Zemanová, M. Forbak, J. Korduláková, O. Pavliš, P. Kubíčková, M. Doležal, J. Zitko
520    9_
$a Apart from the SARS-CoV-2 virus, tuberculosis remains the leading cause of death from a single infectious agent according to the World Health Organization. As part of our long-term research, we prepared a series of hybrid compounds combining pyrazinamide, a first-line antitubercular agent, and 4-aminosalicylic acid (PAS), a second-line agent. Compound 11 was found to be the most potent, with a broad spectrum of antimycobacterial activity and selectivity toward mycobacterial strains over other pathogens. It also retained its in vitro activity against multiple-drug-resistant mycobacterial strains. Several structural modifications were attempted to improve the in vitro antimycobacterial activity. The δ-lactone form of compound 11 (11') had more potent in vitro antimycobacterial activity against Mycobacterium tuberculosis H37Rv. Compound 11 was advanced for in vivo studies, where it was proved to be nontoxic in Galleria mellonella and zebrafish models, and it reduced the number of colony-forming units in spleens in the murine model of tuberculosis. Biochemical studies showed that compound 11 targets mycobacterial dihydrofolate reductases (DHFR). An in silico docking study combined with molecular dynamics identified a viable binding mode of compound 11 in mycobacterial DHFR. The lactone 11' opens in human plasma to its parent compound 11 (t1/2 = 21.4 min). Compound 11 was metabolized by human liver fraction by slow hydrolysis of the amidic bond (t1/2 = 187 min) to yield PAS and its starting 6-chloropyrazinoic acid. The long t1/2 of compound 11 overcomes the main drawback of PAS (short t1/2 necessitating frequent administration of high doses of PAS).
650    _2
$a lidé $7 D006801
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a pyrazinamid $x farmakologie $7 D011718
650    12
$a kyselina aminosalicylová $x farmakologie $7 D010131
650    _2
$a dánio pruhované $7 D015027
650    12
$a COVID-19 $7 D000086382
650    _2
$a SARS-CoV-2 $7 D000086402
650    _2
$a antituberkulotika $x chemie $7 D000995
650    12
$a Mycobacterium tuberculosis $7 D009169
650    12
$a tuberkulóza $x farmakoterapie $7 D014376
650    _2
$a laktony $7 D007783
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Šlechta, Petr $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, Hradec Králové 500 05, Czech Republic
700    1_
$a Jand'ourek, Ondřej $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, Hradec Králové 500 05, Czech Republic
700    1_
$a Konečná, Klára $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, Hradec Králové 500 05, Czech Republic
700    1_
$a Paterová, Pavla $u Department of Clinical Microbiology, University Hospital, Sokolská 581, Hradec Králové 500 05, Czech Republic
700    1_
$a Bárta, Pavel $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, Hradec Králové 500 05, Czech Republic
700    1_
$a Novák, Martin $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, Hradec Králové 500 05, Czech Republic $u Biomedical Research Center, University Hospital Hradec Kralove, Sokolská 581, Hradec Králové 500 05, Czech Republic
700    1_
$a Kučera, Radim $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, Hradec Králové 500 05, Czech Republic
700    1_
$a Dal, Nils-Jørgen Knudsen $u Department of Biosciences, University of Oslo, Blindernveien 31, Oslo 0371, Norway
700    1_
$a Fenaroli, Federico $u Department of Biosciences, University of Oslo, Blindernveien 31, Oslo 0371, Norway $1 https://orcid.org/0000000290608786
700    1_
$a Zemanová, Júlia $u Department of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava, Mlynská Dolina, Ilkovičova 6, Bratislava 84215, Slovakia
700    1_
$a Forbak, Martin $u Department of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava, Mlynská Dolina, Ilkovičova 6, Bratislava 84215, Slovakia
700    1_
$a Korduláková, Jana $u Department of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava, Mlynská Dolina, Ilkovičova 6, Bratislava 84215, Slovakia
700    1_
$a Pavliš, Oto $u Military Health Institute, Military Medical Agency, Tychonova 1, Prague 6 160 01, Czech Republic
700    1_
$a Kubíčková, Pavla $u Military Health Institute, Military Medical Agency, Tychonova 1, Prague 6 160 01, Czech Republic
700    1_
$a Doležal, Martin, $d 1961- $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, Hradec Králové 500 05, Czech Republic $7 jn19981000714
700    1_
$a Zitko, Jan $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, Hradec Králové 500 05, Czech Republic $1 https://orcid.org/0000000301049925 $7 xx0230408
773    0_
$w MED00205751 $t ACS infectious diseases $x 2373-8227 $g Roč. 9, č. 1 (2023), s. 79-96
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36577009 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20240522135311 $b ABA008
999    __
$a ok $b bmc $g 1924979 $s 1190817
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 9 $c 1 $d 79-96 $e 20221228 $i 2373-8227 $m ACS infectious diseases $n ACS infect. dis. $x MED00205751
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace